Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension

Ophthalmology. 2006 Feb;113(2):239-46. doi: 10.1016/j.ophtha.2005.10.045.


Purpose: To compare 24-hour reduction in intraocular pressure (IOP) by latanoprost 0.005%, travoprost 0.004%, and bimatoprost 0.03% in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).

Design: Randomized, double-masked, crossover study.

Participants: Twenty-four patients with POAG and 20 with OH.

Methods: Patients were treated with latanoprost, travoprost, and bimatoprost for 1 month. The treatment sequence was randomized, and washout lasted 30 days for each trial drug. Four 24-hour tonometric curves were recorded for each patient: 1 at baseline and 1 after each treatment period.

Main outcome measures: Intraocular pressure was measured at 3, 6, and 9 am; noon; 3, 6, and 9 pm; and midnight by 2 treatment-masked well-trained evaluators using a handheld electronic tonometer with the patient in supine and sitting positions and a Goldmann applanation tonometer with the patient sitting at the slit lamp. Supine systemic blood pressure was recorded at the same times. A randomized-blocks analysis of variance was used to analyze data.

Results: All 3 drugs were highly effective in reducing IOP when compared to baseline. Mean IOP reductions were similar after the 3 prostaglandin analogs, and none of the differences among treatments reached statistical significance. The drugs' effect was significantly greater during the daytime (9 am-9 pm) than during the nighttime (midnight-6 am) with all prostaglandin analogs. In 7 of 44 patients (16%), nocturnal IOP was significantly higher than diurnal IOP, both at baseline and under the 3 prostaglandin analogs.

Conclusions: From a clinical point of view, the overall results seem to indicate that the 3 prostaglandin analogs are powerful agents in controlling round-the-clock IOP in POAG and OH patients.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Amides
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / therapeutic use*
  • Bimatoprost
  • Blood Pressure / drug effects
  • Circadian Rhythm / drug effects*
  • Cloprostenol / administration & dosage
  • Cloprostenol / analogs & derivatives*
  • Cloprostenol / therapeutic use
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Glaucoma, Open-Angle / drug therapy*
  • Glaucoma, Open-Angle / physiopathology
  • Humans
  • Intraocular Pressure / drug effects*
  • Intraocular Pressure / physiology
  • Latanoprost
  • Lipids / administration & dosage
  • Lipids / therapeutic use*
  • Male
  • Ocular Hypertension / drug therapy
  • Ocular Hypertension / physiopathology
  • Ophthalmic Solutions / administration & dosage
  • Ophthalmic Solutions / therapeutic use
  • Prostaglandins F, Synthetic / administration & dosage
  • Prostaglandins F, Synthetic / therapeutic use*
  • Tonometry, Ocular
  • Travoprost


  • Amides
  • Antihypertensive Agents
  • Lipids
  • Ophthalmic Solutions
  • Prostaglandins F, Synthetic
  • Cloprostenol
  • Latanoprost
  • Bimatoprost
  • Travoprost